Figure 1. Estimated incidence of AIDS, deaths, and persons living with AIDS by quarter-year of diagnosis or death; United States, 1981-2000*.
Figure 2. Perinatally acquired AIDS cases by quarter-year of diagnosis; United States, 1985-2000*.
Figure 3. HIV incidence among injection-drug users in 4 studies; United States, 1984-1998.
Figure 4. Estimates of new HIV infections occurring by gender and risk; United States.
Figure 5. Rectal gonorrhea and sexual risk behavior among MSM; San Francisco, 1994-1998.
Figure 6. Adults and children estimated to be living with HIV/AIDS as of end 2001.
Figure 7. HIV-1 seroprevalence among Thai conscripts by region, 1989-2000.
Figure 8. Routes by which HIV may cross the mucosal barrier.
Figure 9. Two HIV life cycles in resting and activated CD4+ cells.
Figure 10. Clinical stage of HIV disease and risk of HIV transmission.
Figure 11. Summary of antiretroviral seminal plasma: blood plasma concentration ratios.
Figure 12. Clinical significance of seminal concentrations of antiretrovirals.
Figure 13. Antiretroviral penetration in female and male genital tracts.
Figure 14. Summary of ACTG 076 design and results.
Figure 15. Summary of HIVNET 012 design and results.
Figure 16. Algorithm for the management of the HIV-infected pregnant woman.
Figure 17. HIV dynamics following initial exposure.
Figure 18. Reported risk behavior at enrollment and month 24 among MSM in a PEP study.
Figure 19. AIDS density among MSM in San Francisco, 1984-1999.
Figure 20. Trends in AIDS, deaths, and HAART use in San Francisco as of end 2001.
Figure 21. Increasing HIV incidence in San Francisco, 1997-2000.
Figure 22. Incidence of rectal gonorrhea, syphilis, and HIV; Amsterdam, 1991-2001.
Figure 23. HIV incidence among MSM aged < 34 years vs >/= 34 years; Amsterdam, 1991-2001.
Figure 24. Steady vs casual partners as the source of HIV infection among younger and older MSM; Amsterdam, 1984-2000.
Figure 25. Transmission intensity within risk groups and the shape-plus-time scale of an HIV-1 epidemic.
Figure 26. Viral replication and mutation cycle under drug selective pressure.
Figure 27. Effect of multiple treatment interruptions on accumulation of resistance mutations.
Figure 28. Estimated HIV transmission probability based on seminal viral load.
Figure 29. HSV-2 shedding rates among infected individuals.
Figure 30. Summary of design of HPTN 039 Study.